FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 353:2317-2318 December 1, 2005 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Interview Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Fischer, M. PubMed Citation

The Population Council submitted a new drug application to the Food and Drug Administration (FDA) on March 14, 1996, for the progesterone antagonist mifepristone (also known as RU 486) to be used as an abortifacient. The application was based on two studies, involving a total of 4600 women, of the drug's safety and efficacy in the termination of early pregnancies. Four years later, a review article in the Journal¹ cited 14 studies of mifepristone with more than 300 patients per study and a total of 26,000 treated women. By the summer of 2000, mifepristone had been used to treat more . . . [Full Text of this Article]

Source Information

Dr. Greene is a professor of obstetrics, gynecology, and reproductive biology at Harvard Medical School, Boston, director of obstetrics at Massachusetts General Hospital, Boston, and an associate editor of the Journal.

An interview with Dr. Greene can be heard at www.nejm.org.

Related Letters:

Deaths from Clostridium sordellii after Medical Abortion
Baulieu E.-E., Sicard D., Zane S. B., Berg C. J., Fischer M., Reagan S., Zaki S. R.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:1645-1647, Apr 13, 2006. Correspondence

This article has been cited by other articles:

• Fiscella, K., Eisinger, S. H., Meldrum, S., Feng, C., Fisher, S. G., Guzick, D. S. (2006). Effect of Mifepristone for Symptomatic Leiomyomata on Quality of Life and Uterine Size: A Randomized Controlled Trial. Obstet Gynecol 108: 1381-1387 [Abstract] [Full Text]  
• Baulieu, E.-E., Sicard, D., Zane, S. B., Berg, C. J., Fischer, M., Reagan, S., Zaki, S. R. (2006). Deaths from Clostridium sordellii after Medical Abortion. NEJM 354: 1645-1647 [Full Text]  
• Svedas, E., Maciulaitis, R., Stakisaitis, D. (2006). Comment: Analysis of Severe Adverse Events Related to the Use of Mifepristone as an Abortifacient. The Annals of Pharmacotherapy 40: 784-784 [Full Text]  
• Gary, M. M, Harrison, D. J (2006). Authors' Reply. The Annals of Pharmacotherapy 40: 784-785 [Full Text]  
• (2005). Fatal Clostridium sordellii Toxic Shock Syndrome Following Medical Abortion. JWatch Infect. Diseases 2005: 3-3 [Full Text]